Related Experiment Video
Updated: Jun 11, 2026
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
Published on: March 18, 2014
Review of mifamurtide in the treatment of patients with osteosarcoma
Leo Kager1, Ulrike Pötschger, Stefan Bielack
1St. Anna Children's Hospital, Vienna, Austria;
Abstract:
Osteosarcoma is the most common primary malignant tumor of bone. The disease, however, is very rare with less than 2,000 expected patients at all age groups per year within the European Union and the United States of America. With multimodal therapy, which combines multiagent chemotherapy and complete resection of all macroscopically detectable tumors, about 60%-70% of patients with localized osteosarcoma can be cured. The prognosis, however, is still poor for patients with synchronous or metachronous metastatic or nonresectable primary disease, with reported 5-year event-free survival (EFS) rates of less than 30%. Overall, the EFS rate has been rather stable since the introduction of combination chemotherapy including doxorubicin, cisplatin, high-dose methotrexate with leukovorin rescue, and/or ifosfamide. Mifamurtide, a modulator of innate immunity, which activates macrophages and monocytes, which in turn release chemicals with potential tumoricidal effects, may help to control microscopic metastatic disease and has been safely given together with standard adjuvant chemotherapy to patients with high-grade osteosarcoma. Results of the recently published intergroup study 0133 trial from the Children's Cancer and Pediatric Oncology Groups suggest that mifamurtide is a medicine that deserves further investigation in this orphan disease.
Insights
Osteosarcoma, a rare bone cancer, has poor survival rates for metastatic disease despite current therapies. Mifamurtide, an immunotherapy agent, shows promise in controlling microscopic spread and warrants further investigation for osteosarcoma patients.
Area of Science:
- Oncology
- Immunology
- Bone Cancer Research
Background:
- Osteosarcoma is the most common primary bone malignancy, yet it is rare, affecting fewer than 2,000 individuals annually in the EU and US.
- Current multimodal therapy achieves a 60%-70% cure rate for localized osteosarcoma but offers poor prognosis for metastatic or nonresectable disease, with 5-year event-free survival below 30%.
Purpose of the Study:
- To evaluate the potential of mifamurtide, an innate immunity modulator, in managing microscopic metastatic osteosarcoma.
- To assess the safety and efficacy of mifamurtide when administered with standard adjuvant chemotherapy in high-grade osteosarcoma patients.
Main Methods:
- Mifamurtide activates macrophages and monocytes, leading to the release of tumoricidal chemicals.
- The study involved administering mifamurtide alongside standard adjuvant chemotherapy in patients with high-grade osteosarcoma.
Main Results:
- Mifamurtide has been safely administered with standard adjuvant chemotherapy in high-grade osteosarcoma patients.
- The intergroup study 0133 trial suggests mifamurtide's potential in controlling microscopic metastatic disease.
Conclusions:
- Mifamurtide demonstrates potential as a therapeutic agent for osteosarcoma, particularly in managing microscopic metastatic disease.
- Further investigation of mifamurtide is warranted for this rare orphan disease, given its safety profile and potential benefits.
Related Concept Videos
02:56Treatment Resistant Cancers
02:56Treatment Resistent Cancers